key: cord-1021437-r8an93p8
authors: Brown, Bethany
title: Response Letter: Treatment for emerging viruses: Convalescent plasma and COVID-19
date: 2020-09-01
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2020.102929
sha: 8a486f04fd030bd89889d4cc25333637db092448
doc_id: 1021437
cord_uid: r8an93p8

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Response to the Letter to the editor We appreciate the comments of Dr. Pawitan on our paper on Convalescent plasms and COVID -19. We highlighted three case series from China in which severe or critically ill COVID-19 patients were treated with convalescent plasma early in the pandemic. [1] [2] [3] The letter of Dr. Pawitan to the editor has 3 main comments: 1) the information in the text and Table was inconsistent for these 3 case series, 2) the data to date should be interpreted with caution without robust randomized controlled trials to demonstrate efficacy of convalescent plasma, and 3) there are considerations around the safety profile of convalescent plasma.

1) The letter mentioned that the information in the text and 2) Dr. Pawitan mentions that although the results seemed promising from these 3 case series, they need to be interpreted with caution because they are not randomized controlled trials. New data published since this article by Valk, et al. was also cited in the letter. 4 We strongly agree that more robust data from randomized controlled trials are needed to understand the efficacy of convalescent plasma. We also agree that data on this topic is being rapidly generated and reported. Our report only includes the 3 case series published for convalescent plasma used to treat COVID-19 at the time of submission. Results from more randomized controlled trials currently investigating convalescent plasma as a therapy for treatment of COVID-19 are needed. Specifically, considerations will need to be made for antibody titers in the convalescent plasma, volume infused, timing of treatment (for example, days since symptom onset or prophylaxis), confounding variables in the patient population such as age, comorbidities, concomitant treatments, and disease severity. Convalescent plasma is a biologic with variability and protocols for treatment with this biologic may vary study to study, according to protocols published on clinicaltrials.gov. Additionally, COVID-19 case presentation and progression varies greatly based on some variables that have already been identified such as age of the patient and select comorbidities; however, there are many variables that are not yet well understood which may impact clinical outcomes from convalescent COVID 19 plasma and other therapies.

3) The manuscript mentions that TRALI and Antibody Dependent Enhancement may be a risk of convalescent plasma transfusion and suggests that this should be a consideration in the risk-benefit assessment for use of convalescent plasma. Dr. Pawitan also cites reports by Valk et al. (May 2020) and Soner et al. (June 2020), which were published after our manuscript was submitted (April 2020), which describe additional adverse reactions to convalescent plasma including anaphylactic shock, transfusion, TACO, complete immunoglobulin A deficit, and contraindication of convalescent plasma therapy after cytokine storm. We agree that more data on the safety and efficacy of convalescent plasma is rapidly being generated and will need to be considered in the risk-benefit assessment for this therapy. The intent of our summary of the 3 case series using treatment of COVID-19 with convalescent plasma was to include a current information at the time of submission, understanding that the body of evidence would rapidly grow. Additionally, the current safety profile of convalescent plasma for treatment of COVID-19 is favorable and efficacy of this therapy is currently being extensively investigated in larger clinical trials.

The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. The Cochrane database of systematic reviews